PharmiWeb.com - Global Pharma News & Resources
19-Oct-2018

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018 - Featuring Eustralis Pharmaceuticals, Prothena Corporation and Tetra Discovery Partners - ResearchAndMarkets.com

The "Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chronic Traumatic Encephalopathy (CTE) Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chronic Traumatic Encephalopathy (CTE) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Traumatic Encephalopathy (CTE) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively.

Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

  • Eustralis Pharmaceuticals Ltd.
  • Prothena Corporation plc
  • Tetra Discovery Partners LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zmhfbd/chronic_traumatic?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005429/en/

Editor Details

Last Updated: 19-Oct-2018